期刊文献+

阿德福韦酯和拉米夫定初始联合与优化治疗失代偿期乙型肝炎肝硬化的临床对照研究 被引量:4

Clinical control study of primary combination and optimized therapy of lamivudine and adefovir dipivoxil for patients with hepatitis B virus-related decompensated cirrhosis
原文传递
导出
摘要 目的对比分析阿德福韦酯和拉米夫定初始联合与优化治疗失代偿期乙型肝炎肝硬化的临床疗效。方法选择2010年10月~2013年10月在延安大学附属医院进行诊治的失代偿期乙型肝炎肝硬化患者300例,随机分为联合组和优化组,两组均连续治疗1年。联合组采用阿德福韦酯和拉米夫定初始联合治疗,优化组先给予拉米夫定治疗6个月,对患者的血清HBV DNA水平进行检测,如果HBV DNA水平大于1×103拷贝/m L,加用阿德福韦酯,继续治疗6个月。观察和比较两组的HBV DNA复常率、丙氨酸氨基转移酶(ALT)复常率、HBe Ag转阴率,ALT、总胆汁酸(TBIL)、白蛋白水平和腹水消退情况。结果联合组的HBV DNA复常率、ALT复常率和HBe Ag转阴率均明显高于优化组(P〈0.05);两组治疗后的ALT、TBIL、白蛋白好转情况和腹水消退情况均明显优于治疗前(P〈0.05),联合组的改善情况明显优于优化组(P〈0.05);两组治疗前后的肌酸激酶水平和肾功能均无明显差异。结论阿德福韦酯和拉米夫定初始联合治疗失代偿期乙型肝炎肝硬化的临床疗效优于优化治疗。 Objective To analyze the curative effect of primary combination and optimized therapy of lamivudine and adefovir dipivoxil for patients with hepatitis B virus-related decompensated cirrhosis. Methods Totally 300 cases of patients with hepatitis B virus-related decompensated cirrhosis who were treated in Yan'an University Affiliated Hospital from September 2010 to September 2013 were selected and divided into combination group and optimization group randomly. The combination group were given lamivudine combined with adefovir dipivoxil, and the optimized group were given lamivudine treatment for 6 months, then the serum HBV DNA levels were tested, if HBV DNA levels 1×103 copies/m L, plus adefovir dipivoxil. HBV DNA rate, cereal third transaminase rate, HBe Ag overcast rate, cereal third transaminase, total bile acid, albumin levels, and ascites subsided were observed and compared. Results After treatment, recovery rate of HBV DNA, ALT and HBe Ag negative rate of combination group was significantly higher than that of optimal group(P 0.05). After treatment, the improvement of TBIL, ALT, and albumin and the situation of Ascites regression were significantly better than those before treatment(P 0.05), the improvement of the combination group was significantly better than that of the optimization group(P 0.05). The creatine kinase level and renal function before and after treatment had no obvious difference between two groups. Conclusion The combination therapy of lamivudine and adefovir dipivoxil for patients with hepatitis B virus-related decompensated cirrhosis has better curative effect than the optimized therapy.
作者 刘志刚 李春艳 LIU Zhi-gang LI Chun-yan(Infectious Diseases Department, Yan'an University Affiliated Hospital, Yan'an 716000, China)
出处 《药物评价研究》 CAS 2016年第5期813-816,共4页 Drug Evaluation Research
关键词 阿德福韦酯 拉米夫定 失代偿期乙型肝炎肝硬化 Adefovir dipivoxil Lamivudine hepatitis B virus-related decompensated cirrhosis
  • 相关文献

参考文献12

  • 1Fabio G, Desmet V J. Liver biopsy interpretation & the regression of hepatitis B virus related cirrhosis[J]. Ind J Med Res, 2014, 140(2):160–162.
  • 2张玥,周植星,江振洲,黄鑫,张陆勇.治疗慢性乙型肝炎的核苷类药物研究进展[J].药物评价研究,2011,34(2):120-124. 被引量:13
  • 3Anja F, Johann E, Schmitz G H. More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort[J]. J Int Aids Soc, 2014, 17(4Suppl 3):19491–19491.
  • 4Tanaka M, Suzuki F, Seko Y, et al. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B[J]. J Gastroenterol, 2014, 49(3):470–480. doi:10.1007/s00535-013-0779-0.
  • 5慢性乙型肝炎诊断标准(2010年版)[J].中西医结合肝病杂志,2011,21(2):121-122. 被引量:143
  • 6Che Y H, Chongsuvivatwong V, Li L, et al. Financial burden on the families of patients with hepatitis B virus-related liver diseases and the role of public health insurance in Yunnan province of China[J]. Public Health, 2015, 130:13–20.
  • 7Hüsing A, Kabar I, Schmidt H H, et al. Hepatitis C in Special Patient Cohorts:New Opportunities in Decompensated Liver Cirrhosis, End-Stage Renal Disease and Transplant Medicine[J]. Int J Mol Sci, 2015, 16(8):18033–18053. doi:10.3390/ijms160818033.
  • 8Cholongitas E, Papatheodoridis G V, Goulis J, et al. The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis[J]. Ann Gastroenterol, 2015, 28(1):109–117.
  • 9Woo H Y, Choi J Y, Yoon S K, et al. Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus[J]. Clin Mol Hepatol, 2014, 20(2):168–76. doi:10.3350/cmh.2014.20.2.168.
  • 10Mao H, Kang T. Lactic Acidosis during Entecavir Antiviral Treatment in a Patient with Hepatitis B Virus-related Decompensated Cirrhosis[J]. West Ind Med J, 2015, 64(2):165–166.

二级参考文献30

  • 1Dieter Glebe.Recent advances in hepatitis B virus research:A German point of view[J].World Journal of Gastroenterology,2007,13(1):8-13. 被引量:25
  • 2Volker Bruss.Hepatitis B virus morphogenesis[J].World Journal of Gastroenterology,2007,13(1):65-73. 被引量:27
  • 3Calio R,Villani N,Balestra E,et al.Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Research . 1994
  • 4Sato K,Mori M.Current and novel therapies for hepatitis B virus infection. Mini Reviews in Medicinal Chemistry . 2010
  • 5Keeffe E B,,Marcellin P.New and emerging treatment ofchronic hepatitis B. Clinics in Gastroenterology . 2007
  • 6Furman P A,Davis M,Liotta D C,et al.The anti-hepatitis B virus activities,cytotoxicities,and anabolic profiles of the(?)and(+)enantiomers of cis-5-fluoro-1-[2-(hydroxy-methyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrobial Agents and Chemotherapy . 1992
  • 7Seok J I,Lee D K,Lee C H,et al.Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology . 2009
  • 8Yuen M F,Lee S H,Kang H M,et al.Pharmacokinetics of LB80331and LB80317following oral administration of LB80380,a new antiviral agent for chronic hepatitis B(CHB),in healthy adult subjects,CHB patients,and mice. Antimicrobial Agents and Chemotherapy . 2009
  • 9Anna S.F Lok,Brian J.McMahon.Chronic Hepatitis B. Hepatology . 2007
  • 10Liaw YF,Sung JJ,Chow WC,et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease. The New England Journal of Medicine . 2004

共引文献154

同被引文献40

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部